Study of SAR447537 (INBRX-101) Compared to Plasma-derived A1PI Therapy in Adults With AATD Emphysema
← catalyst calendarSponsored by Sanofi (industry) · SNY — their whole pipeline →.
Phase
Phase 2
Status
Completed
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
99actual
Sites
65
Countries
Australia, Denmark, New Zealand +5
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-10-12 | actual | When the study began enrolling |
| Primary completion | 2025-08-06 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-08-06 | actual | The whole study's end, after follow-up |
| First posted | 2023-05-12 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-08-11 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Alpha 1-Antitrypsin Deficiency
- Emphysema
Interventions
- Drug: SAR447537
- Drug: Zemaira — also filed as Respreeza
Primary outcome
what the primary-completion date above is the date OFSerum functional AAT (fAAT) levels at steady-state
measured 32 Weeks
Permalink · SNY's whole pipeline · Catalyst calendar · Every registered study · What changed